BACKGROUND: Anti-Human Epithelial Receptor Type 2 (HER2) antibodies have the ability to induce in vitro apoptosis of glioblastoma (GBM) cells. This study was designed to evaluate the variability of HER2 expression in GBM and its role as a possible prognosis factor. METHODS: Data of 57 patients with GBM and 16 patients with grade III gliomas were retrospectively analyzed. The expression of HER2 was determined by immunohistochemistry and intensity was noted from 0+ to 3+. We compared the HER2 expression in de novo GBM and in GBM resulting from anaplastic transformation of low-grade glioma ("secondary GBM"). Statistical analysis was performed using univariate analysis and the Kaplan-Meier method. FINDINGS: All GBM expressing highly HER2 (2+ and 3+) were de novo GBM. All secondary GBM expressed HER2 with low intensity (0+ and 1+). Survival time was significantly longer when HER2 expression was low (Log Rank test P = 0.04). The patterns of HER2 expression were similar between grade III gliomas and secondary GBM. CONCLUSIONS: To our best knowledge, our study showed for the first time a significant association between HER2 expression and the type of GBM, with subsequent influence on survival rate. GBM with low-HER2 expression are more likely to be secondary GBM, carrying a better prognosis than de novo GBM.
BACKGROUND: Anti-Human Epithelial Receptor Type 2 (HER2) antibodies have the ability to induce in vitro apoptosis of glioblastoma (GBM) cells. This study was designed to evaluate the variability of HER2 expression in GBM and its role as a possible prognosis factor. METHODS: Data of 57 patients with GBM and 16 patients with grade III gliomas were retrospectively analyzed. The expression of HER2 was determined by immunohistochemistry and intensity was noted from 0+ to 3+. We compared the HER2 expression in de novo GBM and in GBM resulting from anaplastic transformation of low-grade glioma ("secondary GBM"). Statistical analysis was performed using univariate analysis and the Kaplan-Meier method. FINDINGS: All GBM expressing highly HER2 (2+ and 3+) were de novo GBM. All secondary GBM expressed HER2 with low intensity (0+ and 1+). Survival time was significantly longer when HER2 expression was low (Log Rank test P = 0.04). The patterns of HER2 expression were similar between grade III gliomas and secondary GBM. CONCLUSIONS: To our best knowledge, our study showed for the first time a significant association between HER2 expression and the type of GBM, with subsequent influence on survival rate. GBM with low-HER2 expression are more likely to be secondary GBM, carrying a better prognosis than de novo GBM.
Authors: J Baselga; D Tripathy; J Mendelsohn; S Baughman; C C Benz; L Dantis; N T Sklarin; A D Seidman; C A Hudis; J Moore; P P Rosen; T Twaddell; I C Henderson; L Norton Journal: J Clin Oncol Date: 1996-03 Impact factor: 44.544
Authors: M Westphal; L Meima; E Szonyi; J Lofgren; H Meissner; W Hamel; K Nikolics; M X Sliwkowski Journal: J Neurooncol Date: 1997-12 Impact factor: 4.130
Authors: Scott E Forseen; Anil Potti; Vijay Koka; Michael Koch; Genise Fraiman; Ralph Levitt Journal: Anticancer Res Date: 2002 May-Jun Impact factor: 2.480
Authors: R Gilbertson; C Wickramasinghe; R Hernan; V Balaji; D Hunt; D Jones-Wallace; J Crolla; R Perry; J Lunec; A Pearson; D Ellison Journal: Br J Cancer Date: 2001-09-01 Impact factor: 7.640
Authors: Paul A Clark; Mari Iida; Daniel M Treisman; Haviryaji Kalluri; Sathyapriya Ezhilan; Michael Zorniak; Deric L Wheeler; John S Kuo Journal: Neoplasia Date: 2012-05 Impact factor: 5.715
Authors: Sharon L Longo; David J Padalino; Sandra McGillis; Kirstin Petersen; Hartmut Schirok; Oliver Politz; Gregory W Canute; Dawn E Post Journal: Invest New Drugs Date: 2011-12-29 Impact factor: 3.850
Authors: Zonghui Ding; Alison Roos; Jean Kloss; Harshil Dhruv; Sen Peng; Patrick Pirrotte; Jennifer M Eschbacher; Nhan L Tran; Joseph C Loftus Journal: Mol Cancer Res Date: 2017-11-08 Impact factor: 5.852